Ymmunobio
Preclinical-stage biotechnology company (Basel, Switzerland & Princeton, NJ, USA) developing antibody-based therapies for solid tumors. Programs include antibodies directed at CEACAM family and NPTXR, pursued across multiple modalities (antibody-drug conjugates, radiopharmaceuticals for imaging/therapy, bispecific T-cell engagers, and CAR-T). The company advances IND-enabling preclinical studies, collaborates with research institutes and industry partners, and has obtained regulatory milestones including an FDA Orphan Drug Designation for a CEACAM-targeting antibody.
Industries
Nr. of Employees
small (1-50)
Products
CEACAM1/5-targeting monoclonal antibody (preclinical)
A human(ized) monoclonal antibody targeting CEACAM family antigens with dual mechanism (checkpoint inhibition and immune agonism); advanced in preclinical studies and granted US FDA Orphan Drug Designation for hepatocellular carcinoma.
NPTXR-targeting antibody platform and modality pipeline (preclinical)
A platform focused on antibodies against a tumor‑exclusive receptor (NPTXR) developed for multiple modalities including dual‑payload ADCs, radiopharmaceutical diagnostics/therapeutics, bispecific T‑cell engagers, and a CAR‑T expansion pathway.
CEACAM1/5-targeting monoclonal antibody (preclinical)
A human(ized) monoclonal antibody targeting CEACAM family antigens with dual mechanism (checkpoint inhibition and immune agonism); advanced in preclinical studies and granted US FDA Orphan Drug Designation for hepatocellular carcinoma.
NPTXR-targeting antibody platform and modality pipeline (preclinical)
A platform focused on antibodies against a tumor‑exclusive receptor (NPTXR) developed for multiple modalities including dual‑payload ADCs, radiopharmaceutical diagnostics/therapeutics, bispecific T‑cell engagers, and a CAR‑T expansion pathway.
Expertise Areas
- Antibody therapeutics for solid tumors
- Antibody-drug conjugate development
- Radiopharmaceutical imaging and therapy
- Bispecific T-cell engager development
Key Technologies
- Monoclonal antibody engineering
- Dual‑payload ADC linker–payload architectures
- Radiochemistry for 177Lu and 161Tb
- PET/SPECT imaging and dosimetry